NCT04144582View on ClinicalTrials.gov

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

December 31, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Sintilimab Combined With Docetaxel Monotherapy

Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w

Trial Locations (2)

410013

Hunan Provincal Tumor Hospital, Changsha

Yongchang Z MD, Changsha

All Listed Sponsors
lead

Yongchang Zhang

OTHER

NCT04144582 - Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter